Last reviewed · How we verify

gonadotopin (HMG)

Yazd Research & Clinical Center for Infertility · FDA-approved active Small molecule

HMG (human menopausal gonadotropin) stimulates the ovaries to produce multiple eggs by mimicking follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

HMG (human menopausal gonadotropin) stimulates the ovaries to produce multiple eggs by mimicking follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Used for Anovulation and infertility in women undergoing assisted reproductive technology (ART), Ovulation induction in women with polycystic ovary syndrome (PCOS), Male hypogonadism and infertility.

At a glance

Generic namegonadotopin (HMG)
SponsorYazd Research & Clinical Center for Infertility
Drug classGonadotropin
TargetFSH receptor (FSHR) and LH receptor (LHR)
ModalitySmall molecule
Therapeutic areaReproductive Medicine / Infertility
PhaseFDA-approved

Mechanism of action

HMG is a purified extract of gonadotropins derived from the urine of postmenopausal women, containing both FSH and LH activity. It binds to FSH and LH receptors on ovarian follicles, promoting follicular growth and maturation. This leads to increased estrogen production and multiple ovulation, making it essential for assisted reproductive technologies.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: